Description
Cartalax (Ala-Glu-Asp) is a synthetic tripeptide of the Khavinson bioregulator class with tissue-specific action on cartilage tissue. The substance was developed at the St. Petersburg Institute for investigating age-related cartilage degeneration models.
Per study reports Cartalax modulates gene expression in chondrocytes via the Khavinson epigenetic mechanism. Preclinical studies describe effects on proteoglycan synthesis, type-II collagen production, and reduction of matrix metalloproteinases in cartilage tissue.
In Russian research reports Cartalax is used as accompaniment in degenerative joint research setups (osteoarthritis models, disc research). International replication is very limited.
Typical application is subcutaneous in 10-20 day courses two to three times per year.
You can order Cartalax as lyophilized peptide in 10-pack at 20mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Cartalax is classified as very mild in the available literature and is among the most well tolerated compounds of the Khavinson bioregulator class. In the available preclinical and limited human studies, no relevant toxic effects have been documented.
Observed in research and reports:
- Injection site: mild redness or transient irritation with subcutaneous use is the most common observation. The tripeptide itself is considered low-reactivity.
- Very thin human data: the data base consists almost entirely of small, Russian-language studies from the Khavinson environment. International replication is very limited, and robust long-term safety data on cartilage use do not exist.
- Course-based pattern: the use described occurs in short 10-20 day courses. No data exist on the safety profile of continuous administration.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Peptide Regulation of Chondrogenic Stem Cell Differentiation - International Journal of Molecular Sciences 2023, Linkova et al: study of short-peptide action on chondrogenic stem cell differentiation.
- Peptides of cartilage tissue: regulation of chondrocyte proliferation, geroprotection and prospects for use in osteoarthrosis - Vrach 2023, Myakisheva et al: review of cartilage peptides including the Cartalax sequence and chondrocyte proliferation.
- Peptide Regulation of Cell Differentiation - Stem Cell Reviews and Reports 2020, Khavinson et al: mechanism review of peptide-induced cell differentiation.
- Peptide bioregulation of aging: results and prospects - Biogerontology 2010, Anisimov and Khavinson: aging mechanism review of the bioregulator class.
